(Q33224084)

24 July 2017

0 references

1 reference

title

Metformin as treatment for overweight and obese adults: a systematic review (English)

1 reference

24 July 2017

0 references

1 reference

1 reference

Kara M Levri

1

1 reference

24 July 2017

Elizabeth Slaymaker

2

1 reference

24 July 2017

Allen Last

3

1 reference

24 July 2017

Julie Yeh

4

1 reference

24 July 2017

Jonathan Ference

5

1 reference

24 July 2017

Frank D'Amico

6

1 reference

24 July 2017

Stephen A Wilson

7

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Annals of Family Medicine

24 July 2017

1 reference

24 July 2017

3

1 reference

24 July 2017

5

1 reference

24 July 2017

457-461

1 reference

Long-term pharmacotherapy for obesity and overweight.

24 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Treatment of binge-eating disorder with topiramate: a clinical case series

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Overweight, obesity, and health risk

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Effect of metformin on food intake in obese subjects.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Treatment of obesity with triiodothyronine and a very-low-calorie liquid formula diet

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Comparison of fenfluramine and metformin in treatment of obesity.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Metabolic effects of metformin in patients with impaired glucose tolerance

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1466911

Fluoxetine: a randomized clinical trial in the treatment of obesity

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16189063

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16189063

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m(2)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16189063

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1370/AFM.343

1 reference

24 July 2017

1 reference

24 July 2017

1 reference